	Application No.	Applicant(s)
	Application No.	Applicant(s)
Madian of Allowal 114	10/660,556	SINHA ET AL.
Notice of Allowability	Examiner	Art Unit
	Rosalynd Keys	1621
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to amendment and remarks filed March 24, 2005.		
2. The allowed claim(s) is/are 36 and 45-50 (now claims 1-7).		
3. The drawings filed on 12 September 2003 are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Sumn Paper No./Mai 8), 7. ☑ Examiner's Am	nal Patent Application (PTO-152) nary (PTO-413), I Date endment/Comment tement of Reasons for Allowance

Application/Control Number: 10/660,556 Page 2

Art Unit: 1621

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be

unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure

consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Matthew E.

Mulkeen on April 22, 2005.

The application has been amended as follows: in claims 48-50 delete Roman numeral "(II)",

which appears after the term neolignan.

Allowable Subject Matter

2. Claims 36 and 45-50 (now claims 1-7) are allowed.

3. Any inquiry concerning this communication or earlier communications from the examiner should

be directed to Rosalynd Keys whose telephone number is 571-272-0639. The examiner can normally be

reached on M and F 3:00-8:00 pm and T-TR 5:30-10:30 am.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this

application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be obtained from

either Private PAIR or Public PAIR. Status information for unpublished applications is available through

Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC)

at 866-217-9197 (toll-free).

Primary Examiner

Art Unit 1621

April 22, 2005

Examiner's amendment

Atty. Dkt. No. 056859-0189

- g) washing the organic layer of step (f) [[(e)]] with brine followed by 10% sodium bicarbonate and another second washing with brine, brine, 10% bicarbonate solution, followed by again brine,
- h) drying the organic layer obtained in step (g) [[(f)]] over anhydrous sodium sulphate, wherein a residue is formed,
- i) chromatographing the residue of step (h) step (g) over silica gel using hexaneehtyl hexane-ethyl acetate mixture to obtain three sets of fractions, and
- j) crystallizing fractions of step (i) [[(h)]] using mixture of hexane and methanol, and
- k) obtaining crystallized fractions of α-asarone 2,4,5-trimethoxyphenylpropane of formula I, 1- (2,4,5-trimethoxy) phenyl-1-propanone of formula IIb and 2,4, neolignan 3-ethyl-2-methyl-3-(2", 4", 5"-trimethoxy) phenyl- -1-(2', 4', 5'-trimethoxy)phenyl-1-propene of formula II.

37 - 44. (Canceled)

- 45. (Currently amended) A process as claimed in claim 36 wherein the effective molar ratio of 2,4,5-trimethoxyp propane and DDQ in step (c) is in the range of 1:1 to 1:2.1
- 46. (Previously presented) A process as claimed in claim 36, wherein the organic solvent in step (c) is acetic acid.
- 47. (Previously presented) A process as claimed in claim 36 wherein the neolignan obtained is termed as NEOLASA-I.
- 48. (Previously presented) A process as claimed in claim 36, wherein the said neolignan (H) has one asymmetric center.
- 49. (Previously presented) A process as claimed in claim 36, wherein the said neolignan (II) obtained provides the opportunity for evaluation of its biological activity.

50. (Previously presented) A process as claimed in claim 36, wherein the said neolignan (M) has aliphatic side chain with one double bond.